

## ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

### SUMMARY

#### Offer Price

- The Offer Price has been determined at HK\$27.80 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

#### Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$27.80 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and the other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$154.8 million (assuming the Over-allotment Option is not exercised). The estimated total listing expenses (assuming that the Over-allotment Option is not exercised) are approximately HK\$69.8 million, or 32.4% of the gross proceeds of the Global Offering, comprising HK\$11.2 million underwriting-related expenses, HK\$32.2 million fees and expenses of legal advisors and Reporting Accountants, and HK\$26.3 million other fees and expenses. The Company intends to apply such net proceeds from the Global Offering in accordance with the purposes as set out in the section headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$32.0 million for 1,211,400 additional H Shares to be issued and allotted upon the exercise of the Over-allotment Option, after deduction of the underwriting fees and commissions and other estimated expenses payable by the Company in connection with the Global Offering. The Company intends to apply the additional net proceeds on a pro-rata basis in accordance with the purposes set out in the section headed “Net Proceeds from the Global Offering” in this announcement in the event that the Over-allotment Option is exercised.

## **Applications and Indications of Interest Received in the Hong Kong Public Offering**

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 1,295 valid applications have been received pursuant to the Hong Kong Public Offering through the **White Form eIPO** service and through the **CCASS EIPO** service for a total of 1,230,600 Hong Kong Offer Shares, representing approximately 1.52 times of the total number of 808,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription in the Hong Kong Public Offering is less than 15 times, the reallocation procedures as described in the section headed “Structure of the Global Offering” in the Prospectus have not been applied. The final number of Offer Shares is 808,000 H Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total number of 865 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, among which, 671 Shareholders, representing approximately 77.57% of the Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, were allocated with one board lot of the H Shares, totalling 134,200 H Shares, representing approximately 16.6% of total Offer Shares under the Hong Kong Public Offering.

## **International Offering**

- The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.19 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 7,268,400 H Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 1,211,400 Offer Shares. Please refer to the section headed “International Offering — Over-allotment Option” in this announcement.
- There are a total of 114 places under the International Offering, among which (i) 90 places, representing 78.95% of the total number of places under the International Offering, have been allotted five or fewer board lots of Offer Shares, totalling 18,800 H Shares, representing 0.26% of the total number of Offer Shares available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 87 places have been allotted one board lot of Offer Shares, representing approximately 76.32% of the total number of places under the International Offering, totalling 17,400 H Shares, representing approximately 0.24% of the Offer Shares available under the International Offering (assuming the Over-allotment Option is not exercised).

### ***Cornerstone Investor***

- Based on the Offer Price of HK\$27.80 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreement, the Cornerstone Investor has subscribed for a total of 5,646,600 Offer Shares, representing (a) approximately 1.35% of the total issued share capital of the Company immediately upon completion of the Global Offering; and (b) approximately 69.91% of the number of Offer Shares under the Global Offering, in each case assuming the Over-allotment Option is not exercised. Please refer to the section headed “Cornerstone Investment” in the Prospectus for further details of the Cornerstone Investor.

### ***Confirmations of Cornerstone Investor, public Shareholders in the Hong Kong Public Offering and placees in the International Offering***

- To the best knowledge of the Company, (i) the Cornerstone Investor is an Independent Third Party and is not a connected person (as defined under the Listing Rules) of the Company; (ii) the Cornerstone Investor is not accustomed to take instructions from the Company, its subsidiaries, the Directors, the Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the H Shares registered in its name or otherwise held by it; and (iii) the subscription of the Offer Shares by the Cornerstone Investor is not financed by the Company, the Directors, the Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates. There are no side agreements or arrangements between the Company and the Cornerstone Investor.
- To the best knowledge of the Company, (i) none of the Offer Shares subscribed by the public and the placees has been financed directly or indirectly by the Company, the Directors, the Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their subsidiaries or their respective close associates; and (ii) none of the public and the placees who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, the Directors, the Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the H Shares registered in his/her/its name or otherwise held by him/her/it. The International Offering is in compliance with the Placing Guidelines.

## **Compliance with Placing Guidelines**

- To the best knowledge, information and belief of the Directors, no Offer Shares placed by or through the Overall Coordinators, and the Underwriters/distributors under the Global Offering have been placed to applicants who are core connected persons (as defined in the Listing Rules) or Directors of the Company, or to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or to any existing Shareholder and its close associates (as set out in paragraph 5(2) of the Placing Guidelines), whether in their own names or through nominees.
- None of the Joint Representatives, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering.
- The Directors confirm that, to the best of their knowledge, information and belief and having made all reasonable enquiries, no Offer Shares under the International Offering have been allocated to placees who are Directors, Supervisors, chief executives, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or beneficial owners of Shares and/or any securities of the Company's subsidiaries or their respective close associates and core connected persons of the Company within the meaning of the Listing Rules, whether in their own names or through nominees, and that all placees and the public who have subscribed for the Offer Shares and their beneficial owners are independent of and not connected with the Company.

## **Over-allotment Option**

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives and the Overall Coordinators on behalf of the International Underwriters, at any time from the Listing Date up to the 30th day after the last day for lodging applications under the Hong Kong Public Offering (i.e. Saturday, October 29, 2022), to require the Company to allot and issue up to an aggregate of 1,211,400 additional H Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 1,211,400 H Shares in the International Offering and such over-allocation will be settled using the H Shares purchased by the Stabilization Manager (or any person acting for it) in the secondary market, exercising the Over-allotment Option in full or in part or through deferred settlement, or by a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at <https://www.jenscare.com> and on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk), respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

## Lock-up Obligations

- The Company, the Controlling Shareholders, all existing Shareholders and the Cornerstone Investor are subject to certain lock-up obligations as set out in the paragraph headed “Lock-up Obligations” in this announcement.

## Results of Allocations

- Results of allocations of the Hong Kong Offer Shares in the Hong Kong Public Offering, including the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on Friday, October 7, 2022 on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company’s website at <https://www.jenscare.com>.
- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **White Form eIPO** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner specified below.
  - in the announcement to be posted on the Company’s website and the Stock Exchange’s website at <https://www.jenscare.com> and [www.hkexnews.hk](http://www.hkexnews.hk), respectively, by no later than 8:00 a.m. on Friday, October 7, 2022. Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results;
  - from the designated results of allocations website at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Friday, October 7, 2022 to 12:00 midnight on Thursday, October 13, 2022; and
  - from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Friday, October 7, 2022, Monday, October 10, 2022, Tuesday, October 11, 2022 and Wednesday, October 12, 2022.

- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **White Form eIPO**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.
- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **White Form eIPO**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

#### **Despatch/Collection of H Share Certificates/e-Refund Payment Instructions/Refund Checks**

- Applicants who applied on **White Form eIPO** for 100,000 or more Hong Kong Offer Shares and who have been wholly or partially successfully allocated Hong Kong Offer Shares and are eligible to collect any refund checks (where applicable) and/or H Share certificates in person may collect Share certificates from the H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Friday, October 7, 2022, or such other date as notified by the Company as the date of despatch/collection of H Share certificates/e-Refund payment instructions/refund monies.
- Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorised representatives bearing letters of authorisation from their corporations stamped with the corporations’ chops. Both individuals and authorised representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Computershare Hong Kong Investor Services Limited.
- H Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 100,000 Hong Kong Offer Shares through the **White Form eIPO** service are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Friday, October 7, 2022.



- H Share certificates for Hong Kong Offer Shares allocated to applicants who applied through the **White Form eIPO** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Friday, October 7, 2022 are expected to be despatched by ordinary post to those entitled to the address specified in the relevant application at their own risk on or before Friday, October 7, 2022.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their H Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Friday, October 7, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS should check and report any discrepancies to HKSCC before 5:00 p.m. on Friday, October 7, 2022, or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS may also check the results of their applications and the amount of refund monies payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). Immediately after the crediting of the Hong Kong Offer Shares to the CCASS Investor Participants stock accounts and the credit of refund monies to the CCASS Investor Participants bank accounts, HKSCC will also make available to the CCASS Investor Participants an activity statement showing the number of Hong Kong Offer Shares credited to their stock accounts and the refund amount credited to their respective designated bank accounts (if any).
- Applicants who applied through the **White Form eIPO** service and paid the application monies from a single bank account will have refund monies (if any) despatched to their application payment accounts in the form of e-Refund payment instructions on Friday, October 7, 2022. Applicants who applied through the **White Form eIPO** service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified in their application instructions in the form of refund cheque(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at their own risk on or before Friday, October 7, 2022. No interest will be paid thereon.
- Refund monies (if any) for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their brokers or custodians on Friday, October 7, 2022.

- H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, October 10, 2022 (Hong Kong time), provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination described in the section headed “Underwriting — Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

### **Public Float**

- The Stock Exchange has granted the Company a waiver from strict compliance with the requirements of Rule 8.08(1) of the Listing Rules. Therefore, the minimum percentage of the H Shares from time to time held by the public shall be the higher of (i) 17.32%; or (ii) such percentage of H Shares to be held by the public after the exercise of the Over-allotment Option, of the enlarged issued share capital of the Company. Immediately following completion of the Global Offering and assuming the Over-allotment Option is not exercised, 64,169,618 H Shares, representing approximately 17.32% of the Company’s enlarged issued share capital would be held by the public, which satisfies the minimum percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1) of the Listing Rules. The Directors confirm that immediately after the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company, (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules) of the Company, (iii) the three largest public Shareholders do not hold more than 50% of the shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules, and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules. The Company will comply with Rule 18A.07 of the Listing Rules that a portion of the total number of the Company’s issued shares with a market capitalization of at least HK\$375 million will be held by the public at the time of Listing.

### **Commencement of Dealings**

- Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Monday, October 10, 2022 (Hong Kong time), dealings in the H Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Monday, October 10, 2022 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each. The stock code of the H Shares is 9877.

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded, and should exercise extreme caution when dealing in H Shares.**



## **OFFER PRICE**

The Offer Price has been determined at HK\$27.80 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

## **NET PROCEEDS FROM THE GLOBAL OFFERING**

Based on the Offer Price of HK\$27.80 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and the other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$154.8 million (assuming the Over-allotment Option is not exercised). The estimated total listing expenses (assuming that the Over-allotment Option is not exercised) are approximately HK\$69.8 million, or 32.4% of the gross proceeds of the Global Offering, comprising HK\$11.2 million underwriting-related expenses, HK\$32.2 million fees and expenses of legal advisors and Reporting Accountants, and HK\$26.3 million other fees and expenses.

The Company intends to apply the net proceeds as follows:

1. Approximately 65.0%, or approximately HK\$100.6 million, will be allocated to the research and development, manufacturing and commercialization of our Core Products, namely, LuX-Valve and Ken-Valve, as follows:
  - approximately 33.3%, or approximately HK\$51.5 million, will be allocated to the research and development, manufacturing and commercialization of our Core Products, namely, LuX-Valve and Ken-Valve, which includes:
    - approximately 12.7%, or approximately HK\$19.7 million, will be used to conduct a series of clinical trials of LuX-Valve;
    - approximately 1.7%, or approximately HK\$2.6 million, will be used for development projects for product improvement to further upgrade and optimize the features of LuX-Valve;
    - approximately 7.1%, or approximately HK\$11.0 million, will be used for expansion of the manufacturing capacity of LuX-Valve; and
    - approximately 11.8%, or approximately HK\$18.3 million, will be used for the preparation of commercial launches (including sales and marketing) of LuX-Valve in China.

- approximately 31.7%, or approximately HK\$49.1 million, will be used for the ongoing research and development activities, further clinical studies, preparation for registration filings, and planned commercial launch of Ken-Valve, which includes:
  - approximately 14.2%, or approximately HK\$22.0 million, will be used to conduct a series of clinical trials of Ken-Valve;
  - approximately 1.9%, or approximately HK\$2.9 million, will be used for development projects for product improvement to further upgrade and optimize the features of Ken-Valve;
  - approximately 4.7%, or approximately HK\$7.3 million, will be used for expansion of the manufacturing capacity of Ken-Valve; and
  - approximately 10.9%, or approximately HK\$16.9 million, will be used for the preparation of commercial launches (including sales and marketing) of Ken-Valve in China.
  
- 2. approximately 25.0%, or approximately HK\$38.7 million, will be allocated to the research and development, clinical trials and product registration of other product candidates in our pipeline, including LuX-Valve Plus, KenFlex and mitral valve products, which includes:
  - approximately 17.0%, or approximately HK\$26.3 million, will be used for the ongoing research and development activities of LuX-Valve Plus in China and other countries, which include:
    - approximately 4.4%, or approximately HK\$6.8 million, will be used for confirmatory clinical trials in China;
    - approximately 12.6%, or approximately HK\$19.5 million, will be used for product registration of LuX-Valve Plus in the EU.
  - approximately 4.0%, or approximately HK\$6.2 million, will be used for the ongoing research and development activities of KenFlex in China, including conducting confirmatory clinical trials;
  - approximately 4.0%, or approximately HK\$6.2 million, will be used for the ongoing research and development activities of our mitral valve products, primarily confirmatory clinical trials for JensClip in China; and

3. approximately 10.0%, or approximately HK\$15.5 million, will be used for our working capital and general corporate purposes.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$32.0 million for 1,211,400 additional H Shares to be issued and allotted upon the exercise of the Over-allotment Option.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

## **APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING**

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. At the close of the application lists at 12:00 noon on Thursday, September 29, 2022, a total of 1,295 valid applications have been received pursuant to the Hong Kong Public Offering through the **White Form eIPO** service and through the **CCASS EIPO** service for a total of 1,230,600 Hong Kong Offer Shares, representing approximately 1.52 times of the total number of 808,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 1,294 valid applications in respect of a total of 826,600 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$28.80 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) of HK\$5 million or less, representing approximately 2.05 times of the 404,000 Hong Kong Offer Shares initially comprised in Pool A; and
- 1 valid applications in respect of a total of 404,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$28.80 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) of more than HK\$5 million, representing 1 time of the 404,000 Hong Kong Offer Shares initially comprised in Pool B.

No application has been rejected due to invalid application. No multiple or suspected multiple applications have been identified and rejected. No application has been rejected due to dishonored payment. No application for more than 404,000 Hong Kong Offer Shares (being 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the over-subscription in the Hong Kong Public Offering is less than 15 times, the reallocation procedures as described in the section headed “Structure of the Global Offering” in the Prospectus have not been effected. The final number of Offer Shares under the Hong Kong Public Offering is 808,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total number of 865 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, among which, 671 Shareholders, representing approximately 77.57% of the Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, were allocated with one board lot of the Offer Shares, totalling 134,200 Shares, representing approximately 16.6% of total Offer Shares under the Hong Kong Public Offering.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the section headed “Basis of Allocation under the Hong Kong Public Offering” below.

## **INTERNATIONAL OFFERING**

The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.19 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 7,268,400 Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 1,211,400 Offer Shares.

There are a total of 114 places under the International Offering, among which (i) 90 places, representing 78.95% of the total number of places under the International Offering, have been allotted five or fewer board lots of Offer Shares, totalling 18,800 H Shares, representing 0.26% of the total number of Offer Shares available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 87 places have been allotted one board lot of Offer Shares, representing approximately 76.32% of the total number of places under the International Offering, totalling 17,400 H Shares, representing approximately 0.24% of the Offer Shares available under the International Offering (assuming the Over-allotment Option is not exercised).

## Cornerstone Investor

Based on the Offer Price of HK\$27.80 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreement as disclosed in the section headed “Cornerstone Investment” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investor is determined as set out below:

<b>Name of Cornerstone Investor</b>	<b>Total Investment Amount (US\$ million)</b>	<b>Number of Offer Shares to be acquired</b>	<b>Approximate % of the Offer Shares</b>	<b>Approximate % of the total Shares in issue<sup>(1)</sup></b>
Lifetech Scientific Corporation (“Lifetech”)	20.0	5,646,600	69.91%	1.35%
<b>Total</b>	<b>20.0</b>	<b>5,646,600</b>	<b>69.91%</b>	<b>1.35%</b>

Notes:

- (1) Assuming the Over-allotment Option is not exercised.
- (2) Percentage figures in the table above are subject to rounding down to the nearest whole board lot of 200 H Shares.

To the best knowledge of the Company, (i) the Cornerstone Investor is an Independent Third Party and is not a connected person (as defined under the Listing Rules) of the Company; (ii) the Cornerstone Investor is not accustomed to take instructions from the Company, its subsidiaries, the Directors, the Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or their respective close associates in relation to the acquisition, disposal, voting, or other disposition of H Shares registered in its name or otherwise held by it; and (iii) the subscription of the Offer Shares by the Cornerstone Investor is not financed by the Company, the Directors, the Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates. The Cornerstone Investor has confirmed that all necessary approvals have been obtained with respect to the Cornerstone Placing and that no specific approval from any stock exchange (if relevant) or its shareholders is required for the cornerstone investment as the Cornerstone Investor has general authority to invest.

As confirmed by the Cornerstone Investor, its subscription under the Cornerstone Placing would be financed by its own internal resources. There are no side arrangements or agreements between the Company and the Cornerstone Investor or any benefit, direct or indirect, conferred on the Cornerstone Investor by virtue of or in relation to the Cornerstone Placing, other than a guaranteed allocation of the relevant Offer Shares at the Offer Price.

The Cornerstone Placing will form part of the International Offering, and the Cornerstone Investor will not subscribe for any Offer Shares under the Global Offering other than pursuant to the Cornerstone Investment Agreement. The Offer Shares to be subscribed by the Cornerstone Investor will rank pari passu in all respect with the fully paid H Shares in issue and will be counted towards the public float of the Company under Rule 8.08 of the Listing Rules. Such Offer Shares will not count towards the public float for the purpose of Rule 18A.07 of the Listing Rules. Immediately following the completion of the Global Offering, the Cornerstone Investor will not become a substantial Shareholder (as defined in the Listing Rules) of the Company and will not have any Board representation in the Company. The Cornerstone Investor does not have any preferential rights under the Cornerstone Investment Agreement compared with other public Shareholders, other than a guaranteed allocation of the Offer Shares at the Offer Price.

The Cornerstone Investor has, where applicable, agreed that without the prior written consent of each of the Company, the Joint Sponsors and the Joint Representatives, it will not, and will cause its affiliates not to, whether directly or indirectly, at any time during the period of six months from the Listing Date (the “**Lock-up Period**”), (i) dispose of, in any way, any of the Offer Shares it has purchased pursuant to the Cornerstone Investment Agreement or any interest in any company or entity holding any of such Offer Shares; (ii) allow itself to undergo a change of control (as defined in Hong Kong Takeovers Code) at the level of its ultimate beneficial owner; or (iii) enter into any transactions directly or indirectly with the same economic effect as any aforesaid transaction, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries which will be bound by the same obligations of the Cornerstone Investor, including the Lock-up Period restriction.

Please refer to the section headed “Cornerstone Investment” in the Prospectus for further details relating to the Cornerstone Investor.

To the best knowledge of the Company, (i) none of the Offer Shares subscribed by the public and the placees has been financed directly or indirectly by the Company, the Directors, the Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their subsidiaries or their respective close associates, and (ii) none of the public and the placees who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, the Directors, the Supervisors, chief executive, substantial Shareholders, existing Shareholders or any of their subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the H Shares registered in his/her/its name or otherwise held by him/her/it. The International Offering is in compliance with the Placing Guidelines.

To the best knowledge, information and belief of the Directors, no Offer Shares placed by or through the Overall Coordinators, and the Underwriters/distributors under the Global Offering have been placed to applicants who are core connected persons (as defined in the Listing Rules) or Directors of the Company, or to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or to any existing Shareholder and its close associates (as set out in paragraph 5(2) of the Placing Guidelines), whether in their own names or through nominees.



## Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives and the Overall Coordinators on behalf of the International Underwriters, at any time from the Listing Date up to the 30th day after the last day for lodging applications under the Hong Kong Public Offering (i.e. Saturday, October 29, 2022), to require the Company to allot and issue up to an aggregate of 1,211,400 additional Offer Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering, if any.

There has been an over-allocation of 1,211,400 Offer Shares in the International Offering and such over-allocation will be settled using H Shares purchased by the Stabilization Manager (or its affiliates or any person acting for it) in the secondary market, exercising the Over-allotment Option in full or in part or through deferred settlement, or by a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at <https://www.jenscare.com> and on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk), respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

## Lock-up Obligations

The Company, the Controlling Shareholders, all existing Shareholders and the Cornerstone Investor are subject to certain obligations in relation to the Shares (the “**Lock-up Obligations**”). The major terms of the Lock-Up Obligations are as follows:

Name	Class of Shares	Number of Shares subject to the Lock-up Obligations upon Listing	% of shareholding in the Company subject to the Lock-up Obligations upon Listing <sup>(1)</sup>	Last day subject to the lock-up period
------	-----------------	--	---	--

*The Company (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)*

	N/A	N/A	N/A	April 9, 2023 <sup>(2)</sup>
--	-----	-----	-----	------------------------------

*Controlling Shareholders (subject to lock-up obligations pursuant to the Hong Kong Underwriting Agreement and applicable PRC laws and regulations)*

Mr. LV Shiwen and Ms. LI Hui<sup>(4)</sup>

Mr. LV Shiwen (in his personal capacity)	Domestic Shares	25,516,296	6.12%	October 9, 2023 <sup>(3)</sup>
	H Shares	13,739,544	3.29%	October 9, 2023 <sup>(3)</sup>
Hainan Maidi Enterprise Management L.P. (Limited Partnership) (“ <b>Hainan Maidi</b> ”)	Domestic Shares	41,236,200	9.88%	October 9, 2023 <sup>(3)</sup>
Shanghai Shidi Industrial Development Co., Ltd. (“ <b>Shanghai Shidi</b> ”)	Domestic Shares	25,589,304	6.13%	October 9, 2023 <sup>(3)</sup>
	H Shares	13,778,856	3.30%	October 9, 2023 <sup>(3)</sup>

Name	Class of Shares	Number of Shares subject to the Lock-up Obligations upon Listing	% of shareholding in the Company subject to the Lock-up Obligations upon Listing <sup>(1)</sup>	Last day subject to the lock-up period
Ningbo Sangdi Investment Management L.P. (Limited Partnership) (“Ningbo Sangdi”)	Domestic Shares	20,107,386	4.82%	October 9, 2023 <sup>(3)</sup>
	H Shares	10,827,054	2.60%	October 9, 2023 <sup>(3)</sup>
Ningbo Mukang Venture Capital Partnership (Limited Partnership) (“Ningbo Mukang”)	Domestic Shares	16,829,046	4.03%	October 9, 2023 <sup>(3)</sup>
	H Shares	9,061,794	2.17%	October 9, 2023 <sup>(3)</sup>
Ningbo Linfeng Biotechnology Co., Ltd. (“Ningbo Linfeng”)	Domestic Shares	13,720,590	3.29%	October 9, 2023 <sup>(3)</sup>
	H Shares	7,388,010	1.77%	October 9, 2023 <sup>(3)</sup>
Ningbo Kefeng Investment Management L.P. (Limited Partnership) (“Ningbo Kefeng”)	Domestic Shares	8,448,804	2.03%	October 9, 2023 <sup>(3)</sup>
	H Shares	4,549,356	1.09%	October 9, 2023 <sup>(3)</sup>
	Domestic Shares	151,447,626	36.30%	
	H Shares	59,344,614	14.23%	
Sub-total		210,792,240	50.53%	

*All other existing Shareholders (including the Pre-IPO Investors but excluding Controlling Shareholders above) (subject to lock-up obligations pursuant to the applicable PRC laws and regulations)*

Hainan Hualing Investment L.P. (Limited Partnership)	Domestic Shares	32,727,240	7.85%	October 9, 2023 <sup>(3)</sup>
Zhuhai Yuheng Equity Investment L.P. (Limited Partnership)	Domestic Shares	18,618,120	4.46%	October 9, 2023 <sup>(3)</sup>
Suzhou Chenzhide Investment L.P. (Limited Partnership)	Domestic Shares	9,926,280	2.38%	October 9, 2023 <sup>(3)</sup>
	H Shares	4,254,120	1.02%	October 9, 2023 <sup>(3)</sup>
Qiushixingde (Tianjin) Investment Center (Limited Partnership)	Domestic Shares	9,360,000	2.24%	October 9, 2023 <sup>(3)</sup>
	H Shares	5,040,000	1.21%	October 9, 2023 <sup>(3)</sup>
China Life Chengda (Shanghai) Healthcare Equity Investment Center (Limited Partnership)	Domestic Shares	8,509,176	2.04%	October 9, 2023 <sup>(3)</sup>
	H Shares	4,581,864	1.10%	October 9, 2023 <sup>(3)</sup>
Tianjin Fanchuan Management Consulting L.P. (Limited Partnership)	Domestic Shares	5,994,144	1.44%	October 9, 2023 <sup>(3)</sup>
	H Shares	3,227,616	0.77%	October 9, 2023 <sup>(3)</sup>
Beijing PICC Healthcare Investment Fund, L.P.	Domestic Shares	5,199,948	1.25%	October 9, 2023 <sup>(3)</sup>
	H Shares	2,799,972	0.67%	October 9, 2023 <sup>(3)</sup>
Suzhou Proxima Venture Investment L.P. (Limited Partnership)	Domestic Shares	2,618,280	0.63%	October 9, 2023 <sup>(3)</sup>
	H Shares	1,122,120	0.27%	October 9, 2023 <sup>(3)</sup>
GP Healthcare Equity Investment L.P. (Limited Partnership)	Domestic Shares	2,431,260	0.58%	October 9, 2023 <sup>(3)</sup>
	H Shares	1,309,140	0.31%	October 9, 2023 <sup>(3)</sup>
Tianjin Fanshi Management Consulting L.P. (Limited Partnership)	Domestic Shares	1,990,170	0.48%	October 9, 2023 <sup>(3)</sup>
	H Shares	1,071,630	0.26%	October 9, 2023 <sup>(3)</sup>
Shanghai Changxiang Medical Technology Center (Limited Partnership)	Domestic Shares	1,890,954	0.45%	October 9, 2023 <sup>(3)</sup>
	H Shares	1,018,206	0.24%	October 9, 2023 <sup>(3)</sup>

Name	Class of Shares	Number of Shares subject to the Lock-up Obligations upon Listing	% of shareholding in the Company subject to the Lock-up Obligations upon Listing <sup>(1)</sup>	Last day subject to the lock-up period
CICC Pucheng Investment Co., Ltd	Domestic Shares	1,701,882	0.41%	October 9, 2023 <sup>(3)</sup>
	H Shares	916,398	0.22%	October 9, 2023 <sup>(3)</sup>
AUT-VII HK Holdings Limited	Unlisted	21,750,000	5.21%	October 9, 2023 <sup>(3)</sup>
	Foreign Shares			
Janecox Investment IV HK Limited	Unlisted	6,825,000	1.64%	October 9, 2023 <sup>(3)</sup>
	Foreign Shares			
Duckling Fund L.P.	H Shares	3,675,000	0.88%	October 9, 2023 <sup>(3)</sup>
	Unlisted	3,536,578	0.85%	October 9, 2023 <sup>(3)</sup>
FOREBRIGHT KEEN ASCENT LIMITED	Foreign Shares			
	H Shares	1,904,312	0.46%	October 9, 2023 <sup>(3)</sup>
Hangzhou Chende Investment L.P. (Limited Partnership)	Unlisted	1,050,000	0.25%	October 9, 2023 <sup>(3)</sup>
	Foreign Shares			
Hangzhou Proxima Innovative Investment L.P. (Limited Partnership)	H Shares	1,050,000	0.25%	October 9, 2023 <sup>(3)</sup>
	H Shares	10,935,720	2.62%	October 9, 2023 <sup>(3)</sup>
Mr. WU Danke	H Shares	5,958,720	1.43%	October 9, 2023 <sup>(3)</sup>
CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP	H Shares	3,504,960	0.84%	October 9, 2023 <sup>(3)</sup>
Mr. MA Ji	H Shares	3,000,000	0.72%	October 9, 2023 <sup>(3)</sup>
FutureX Investment I Company Limited	H Shares	2,499,840	0.60%	October 9, 2023 <sup>(3)</sup>
ChinaAMC Summerbrook Fund	H Shares	2,100,000	0.50%	October 9, 2023 <sup>(3)</sup>
Start New Limited	H Shares	2,100,000	0.50%	October 9, 2023 <sup>(3)</sup>
Sub-total		<u>198,298,650</u>	<u>47.53%</u>	
<i>Cornerstone Investor (subject to lock-up obligations pursuant to their respective Cornerstone Investment Agreements)</i>				
Lifetech <sup>(5)</sup>	H Shares	<u>5,646,600</u>	<u>1.35%</u>	April 9, 2023 <sup>(3)</sup>
Sub-total		<u>5,646,600</u>	<u>1.35%</u>	
<b>Grand Total</b>		<u><b>414,737,490</b></u>	<u><b>99.42%</b></u>	

*Notes:*

- (1) Assuming the Over-Allotment Option is not exercised.
- (2) The Company may not issue Shares prior to the indicated date except otherwise permitted by the Listing Rules.
- (3) The Controlling Shareholders, all other existing Shareholders and the Cornerstone Investor may dispose of or transfer Shares without any lock-up obligation after the indicated date.
- (4) Pursuant to a concert party agreement dated March 16, 2021 entered into by Mr. LV Shiwen and Ms. LI Hui, Mr. LV Shiwen and Ms. LI Hui confirmed that they have been acting in concert in the management and operation of the Group since January 1, 2018, and they have agreed to continue to act in concert and reach consensus on proposals related to the daily management and operation of the Group presented to the general meeting of the Shareholders of the Company for voting. Upon Listing and assuming no exercise of the Over-allotment Option, Mr. LV Shiwen and Ms. LI Hui are entitled to exercise voting rights of approximately 50.53% voting rights in the Company. In particular, Mr. LV Shiwen is able to exercise approximately 36.03% voting rights in the Company through (i) his personal capacity as to approximately 9.41%; (ii) Ningbo Sangdi as to approximately 7.42%; (iii) Ningbo Mukang as to approximately 6.21%; (iv) Ningbo Kefeng as to approximately 3.12%; and (v) Hainan Maidu as to approximately 9.88%. Mr. LV Shiwen controls the general partner of each of Ningbo Sangdi, Ningbo Mukang, Ningbo Kefeng and Hainan Maidu, namely, Ningbo Dixiang Venture Capital Co., Ltd.. Ningbo Dixiang Venture Capital Co., Ltd. is entitled to exercise the voting power held by each of Ningbo Sangdi, Ningbo Mukang, Ningbo Kefeng and Hainan Maidu in the Company pursuant to their respective partnership agreements. Ms. LI Hui is able to exercise approximately 14.50% voting rights in the Company through (a) Shanghai Shidi as to approximately 9.44%; and (b) Ningbo Linfeng as to approximately 5.06%.
- (5) The number of Shares set out here comprises H Shares acquired under the Cornerstone Investment Agreement.
- (6) Percentage figures in the table above are subject to rounding down to the nearest whole board lot of 200 H Shares.
- (7) Percentage figures in the table above are subject to rounding adjustments.

## BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus, 1,295 valid applications made by the public through the **White Form eIPO** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

### Pool A

Number of shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted to the total number of shares applied for
200	1,024	594 out of 1,024 to receive 200 Shares	58.01%
400	78	200 Shares plus 12 out of 78 to receive additional 200 Shares	57.69%
600	38	200 Shares plus 27 out of 38 to receive additional 200 Shares	57.02%
800	14	400 Shares plus 3 out of 14 to receive additional 200 Shares	55.36%
1,000	41	400 Shares plus 28 out of 41 to receive additional 200 Shares	53.66%
1,200	8	600 Shares	50.00%
1,400	8	600 Shares plus 4 out of 8 to receive additional 200 Shares	50.00%
1,600	10	600 Shares plus 9 out of 10 to receive additional 200 Shares	48.75%
1,800	6	800 Shares plus 2 out of 6 to receive additional 200 Shares	48.15%
2,000	29	800 Shares plus 20 out of 29 to receive additional 200 Shares	46.90%
3,000	11	1,400 Shares	46.67%
4,000	7	1,800 Shares	45.00%
5,000	2	2,200 Shares	44.00%
6,000	2	2,600 Shares	43.33%
7,000	7	3,000 Shares	42.86%
8,000	1	3,400 Shares	42.50%
10,000	6	4,200 Shares	42.00%
50,000	1	21,000 Shares	42.00%
160,000	1	67,200 Shares	42.00%
<b>TOTAL:</b>	<b><u>1,294</u></b>	<b>Total number of Pool A successful applicants: 864</b>	

### Pool B

Number of shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted to the total number of shares applied for
404,000	<u>1</u>	404,000 Shares	100.00%
<b>TOTAL:</b>	<b><u>1</u></b>	<b>Total number of Pool B successful applicants: 1</b>	

The final number of Offer Shares under the Hong Kong Public Offering is 808,000 H Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

## RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **White Form eIPO** service or through the **CCASS eIPO** service, including the Hong Kong identity card, passport, Hong Kong business registration or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares successfully applied for, will be made available at the times and date and in the manner specified below:

- in the announcement to be posted on the Company’s website at <https://www.jenscare.com> and the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) by no later than 8:00 a.m. on Friday, October 7, 2022. Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results;
- from the designated results of allocations website at [www.iporesults.com](http://www.iporesults.com) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Friday, October 7, 2022 to 12:00 midnight on Thursday, October 13, 2022; and
- from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. from Friday, October 7, 2022 to Wednesday, October 12, 2022, (except Saturday, Sunday and public holiday in Hong Kong).

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **White Form eIPO**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **White Form eIPO**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.



The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published from Friday, October 7, 2022 on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company's website at <https://www.jenscare.com>.

## SHAREHOLDING CONCENTRATION ANALYSIS

A summary of allotment results under the International Offering is set out below:

- Top 1, 5, 10, 20 and 25 of the places in the International Offering:

Placee	Subscription	Shares held following the Global Offering	Subscription as % of International Offering (assuming the Over-allotment Option is not exercised)	Subscription as % of International Offering (assuming the Over-allotment Option is fully exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is fully exercised)	% of the total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)	% of the total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)
Top 1	5,646,600	5,646,600	77.69%	66.59%	69.91%	60.80%	1.35%	1.35%
Top 5	8,438,000	8,438,000	116.09%	99.51%	104.48%	90.85%	2.02%	2.02%
Top 10	8,444,200	8,444,200	116.18%	99.58%	104.55%	90.92%	2.02%	2.02%
Top 20	8,456,200	8,456,200	116.34%	99.72%	104.70%	91.05%	2.03%	2.02%
Top 25	8,461,600	8,461,600	116.42%	99.79%	104.77%	91.10%	2.03%	2.02%

- Top 1, 5, 10, 20 and 25 of all the Shareholders upon Listing:

Shareholder	Subscription of International Offer Shares	Subscription of Global Offering	Shares held following the Global Offering	Subscription of International Offering as % of International Offering (assuming the Over-allotment Option is not exercised)	Subscription of International Offering as % of International Offering (assuming the Over-allotment Option is fully exercised)	Subscription of Global Offering as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription of Global Offering as % of total Offer Shares (assuming the Over-allotment Option is fully exercised)	% of the total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)	% of the total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)
Top 1	-	-	210,792,240	0.00%	0.00%	0.00%	0.00%	50.53%	50.38%
Top 5	-	-	333,903,720	0.00%	0.00%	0.00%	0.00%	80.04%	79.81%
Top 10	5,646,600	5,646,600	382,623,960	77.69%	66.59%	69.91%	60.80%	91.72%	91.45%
Top 20	8,394,400	8,394,400	413,285,290	115.49%	98.99%	103.94%	90.38%	99.07%	98.78%
Top 25	8,422,400	8,893,600	417,984,490	115.88%	99.32%	110.12%	95.76%	100.20%	99.91%

- Top 1, 5, 10, 20 and 25 of all the holders of the H Shares of the Company (the “H Shareholders”) upon Listing:

H Shareholder	Subscription of the International Offer Shares	Subscription of Global Offering	Number of H Shares held upon Listing	Number of Shares held upon Listing	Subscription as % of the total number of H Shares allocated under the International Offering (assuming the Over-allotment Option is not exercised)	Subscription as % of the total number of H Shares allocated under the International Offering (assuming the Over-allotment Option is fully exercised)	Subscription as % of the total number of H Shares allocated under the Global Offering (assuming the Over-allotment Option is not exercised)	Subscription as % of the total number of H Shares allocated under the Global Offering (assuming the Over-allotment Option is fully exercised)	H Shares held as % of total number of H Shares (assuming the Over-allotment Option is not exercised)	H Shares held as % of total number of H Shares (assuming the Over-allotment Option is fully exercised)	Shares held as % of the total issued share capital upon Listing (assuming the Over-allotment Option is not exercised)	Shares held as % of the total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised)
Top 1	-	-	59,344,614	210,792,240	0.00%	0.00%	0.00%	0.00%	45.10%	44.69%	50.53%	50.38%
Top 5	5,646,600	5,646,600	95,976,894	276,154,080	77.69%	66.59%	69.91%	60.80%	72.94%	72.27%	66.20%	66.01%
Top 10	5,646,600	5,646,600	114,162,936	316,033,560	77.69%	66.59%	69.91%	60.80%	86.76%	85.96%	75.76%	75.54%
Top 20	8,394,400	8,394,400	131,908,632	344,389,930	115.49%	98.99%	103.94%	90.38%	100.24%	99.33%	82.55%	82.32%
Top 25	8,436,400	8,928,600	132,442,832	344,924,130	116.07%	99.49%	110.55%	96.13%	100.65%	99.73%	82.68%	82.44%

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded, and should exercise extreme caution when dealing in H Shares.**